Drug intelligence / Profile preview

APR003

Development stage: Unknown
Lead developer: Apros Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

APR003 is a small molecule TLR7 agonist designed to concentrate in the gastrointestinal tract and liver, promoting local immune activation. It is used for the treatment of advanced colorectal cancer with malignant liver lesions. The drug aims to enhance anti-tumor immune responses by activating dendritic cells and natural killer cells, thereby turning "cold" tumors into "hot" immune-permissive tumors.

Targets

TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on APR003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APR003.

Explore the full profile